登录新浪财经APP 搜索【信披】查看更多考评等级 上海柘中集团股份有限公司（以下简称"公司"）于2022年9月参与投资设立柘中君信（上海）私募基金 合伙企业（有限合伙）（以下简称"柘中君信基金"），基金认缴出资总额为12亿元，公司作为有限合伙 人参与投资，认缴出资金额3亿元，占其总规模的25%。具体内容详见公司于2022年9月8日披露的《关 于公司与专业投资机构合作进行对外投资的公告》（公告编号：2022-57）。 公司于2025年8月2日披露了《关于公司转让基金份额暨对外投资的进展公告》（公告编号：2025- 34），公司分别与上海悦来港实业集团有限公司（以下简称"悦来港"）、君信（上海）股权投资基金管 理有限公司（以下简称"君信投管"）签署财产份额转让协议。其中，公司将持有的柘中君信基金认缴未 实缴部分对应的3.33%的财产份额转让给悦来港，转让的基金份额对应认缴出资金额4,000万元，实缴出 资金额0元，转让价款0元；将持有的柘中君信基金认缴未实缴部分对应的1.67%的财产份额转让给君信 投管，转让的基金份额对应认缴出资金额2,000万元，实缴出资金额0元，转让价款0元，转让完成后公 司不再承担对应基金 ...

Group 1 - The company, Shandong Buchang Pharmaceutical Co., Ltd., is participating as a limited partner in the investment fund Hainan Sanya Yuhai Growth Equity Investment Fund Partnership, which is undergoing a capital reduction due to the withdrawal of its limited partner, Green Leaf Investment Group [1][3] - Following the withdrawal of Green Leaf Investment Group and the completion of the capital reduction, the total capital of Hainan Sanya Yuhai will decrease from 614.50 million to 514.50 million, while the company's subscribed capital remains unchanged, resulting in an increase in its ownership percentage from 16.2734% to 19.4363% [1][3] - The board of directors approved the capital reduction proposal on July 8, 2025, and this matter does not require approval from the shareholders' meeting [2][3] Group 2 - The capital reduction does not constitute a related party transaction and does not fall under the category of significant asset restructuring as defined by the regulations [2][3] - The financial data of Hainan Sanya Yuhai as of December 31, 2024, shows total assets of 238.22 million, total liabilities of 1.25 million, and a net asset of 238.09 million, with a net profit of -9.21 million for the year [2] - As of March 31, 2025, the fund's total assets were 235.79 million, total liabilities were 0.64 million, and net assets were 235.79 million, with a net profit of -0.23 million for the first quarter of 2025 [2][4]